Literature DB >> 7550976

Determination of lansoprazole and five metabolites in plasma by high-performance liquid chromatography.

M D Karol1, G R Granneman, K Alexander.   

Abstract

A high-performance liquid chromatographic method for the determination of lansoprazole, a new proton-pump inhibitor, and five of its metabolites in human plasma is described. Lansoprazole, its metabolites, and internal standard (omeprazole) were extracted into diethyl ether-methylene chloride and separation was obtained using a reversed-phase column under isocratic conditions. The method features monochromatic ultraviolet detection at 285 nm, and single extraction, single evaporation sample handling. The lower limit of quantitation, based on standards with acceptable coefficients of variation, was 10 ng/ml for all compounds. No endogenous compounds were found to interfere. This method has been demonstrated to be suitable for pharmacokinetic studies in humans.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7550976     DOI: 10.1016/0378-4347(95)00068-t

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Appl        ISSN: 1572-6495


  7 in total

1.  Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians.

Authors:  Nicole G Hunfeld; Ron A Mathot; Daan J Touw; Ron H van Schaik; Paul G Mulder; Paul F Franck; Ernst J Kuipers; William P Geus
Journal:  Br J Clin Pharmacol       Date:  2008-01-30       Impact factor: 4.335

2.  Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole.

Authors:  Imad Zalloum; Nancy Hakooz; Tawfiq Arafat
Journal:  Mol Biol Rep       Date:  2011-07-17       Impact factor: 2.316

3.  CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.

Authors:  T Sakai; N Aoyama; T Kita; T Sakaeda; K Nishiguchi; Y Nishitora; T Hohda; D Sirasaka; T Tamura; Y Tanigawara; M Kasuga; K Okumura
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

4.  Association of CYP2C19 polymorphisms and lansoprazole-associated respiratory adverse effects in children.

Authors:  John J Lima; Jason E Lang; Edward B Mougey; Kathryn B Blake; Yan Gong; Janet T Holbrook; Robert A Wise; W G Teague
Journal:  J Pediatr       Date:  2013-04-24       Impact factor: 4.406

5.  Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.

Authors:  Hai-Ling Qiao; Yu-Rong Hu; Xin Tian; Lin-Jing Jia; Na Gao; Li-Rong Zhang; Yu-Zhong Guo
Journal:  Eur J Clin Pharmacol       Date:  2006-01-10       Impact factor: 2.953

6.  Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state.

Authors:  L E Gustavson; J F Kaiser; A L Edmonds; C S Locke; M L DeBartolo; D W Schneck
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

7.  Spectrophotometric determination of certain benzimidazole proton pump inhibitors.

Authors:  A A Syed; Ayesha Syeda
Journal:  Indian J Pharm Sci       Date:  2008 Jul-Aug       Impact factor: 0.975

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.